Somatostatin-like Immunoreactivity Levels Research Articles

Somatostatin Levels in Plasma in Nonsmoking and Smoking Breast‐Feeding Women

The objective of the study was to record how somatostatin levels in plasma are altered in response to breast-feeding during the lactation period and to relate somatostatin levels to the success of the lactational performance and to smoking habits. Fifty-two women were investigated 4 days post partum and 3-4 months later. Blood samples were collected and the levels of somatostatin-like immunoreactivity (below referred to as SLI) were measured with radioimmunoassay. The periods of exclusive breast-feeding and of mixed feeding were assessed as well as the milk yield. Smoking habits were noted. SLI levels were found to be significantly lower on day 4 after delivery, compared to 3-4 months later. Also the type of response to breast-feeding was different. Thus, a significant fall of SLI was seen during breast-feeding at the maternity unit, but not 3-4 months later. Smoking women breast-fed fully for a significantly shorter time than nonsmokers and had significantly higher SLI levels at onset of breast-feeding day 4 post partum. Whether the high somatostatin levels recorded in connection with breast-feeding in smokers are related to the shorter period of breast-feeding seen in this group remains to be established. In addition, the highest levels of somatostatin were seen the day after the very last breast-feeding and a possible role for somatostatin in the weaning process should be explored.

Reduced Lumbar Cerebrospinal Fluid Somatostatin Levels in Alzheimer's Disease and Dementia with Frontotemporal Degeneration

The present study evaluates the cerebrospinal fluid levels of somatostatin-like immunoreactivity (LI) in two types of primary degenerative dementias: dementia of Alzheimer''s disease (DAT) and dementia with frontotemporal cortical degeneration of non-Alzheimer type (which included Pick''s disease). Several studies have documentated reduced concentration of somatostatin-LI in the brain and cerebrospinal fluid (CSF) in DAT. This study confirmed these results and showed in addition reduced CSF levels of somatostatin-LI in frontal lobe dementia (FTD), which has not been shown previously. There was no significant correlation with the duration of the disease. The histopathology and distribution of cortical degeneration in DAT and FTD differs in most aspects but shares the reduction in somatostatin-LI reduction. This suggests involvement of somatostatin neurons in these two types of primary degenerative dementias.

Effects of Acute and Chronic Ethanol Administration and its Withdrawal on the Level and Binding of Somatostatin in Rat Brain

1. Acute ethanol administration resulted in an increase in the total number of specific somatostatin receptors in rat frontoparietal cortex and hippocampus, and a decrease in the level of somatostatin-like immunoreactivity in the hippocampus but not in the frontoparietal cortex. 2. Chronic administration of ethanol caused a decrease in the number of somatostatin receptors in the frontoparietal cortex but not in the hippocampus, although the level of somatostatin-like immunoreactivity was unchanged in both brain areas. 3. A week after suppressing ethanol the value for specific binding of tracer to somatostatin receptors in the frontoparietal cortex was not significantly different from that of the control rats, although the actual number of receptors was slightly lower. 4. These results suggest a possible role for somatostatin in the nervous system during alcoholism and the post-withdrawal reaction.

Fasting and Postprandial Concentrations of Somatostatin-28 and Somatostatin-14 in Type II Diabetes in Men

Recent evidence suggests that somatostatin-28 (SRIF-28), cleaved from prosomatostatin by cells of the upper intestine, acts as a nutrient-stimulated inhibitor of insulin secretion in healthy men. A role for SRIF-28 in the pathophysiology of diabetes has not been previously explored, although several groups have measured circulating somatostatinlike immunoreactivity (SLI) in diabetic subjects. To investigate the possible mediation of abnormal insulin secretion in diabetes by SRIF-28, plasma levels were measured in 10 non-insulin-dependent diabetic men and 9 age- and weight-matched control subjects. Concentrations of SRIF-14 and SLI were also obtained. Subjects were admitted for study after an overnight fast, blood was collected before and at 30-min intervals for 4 h after a fat meal, and plasma samples were analyzed for SRIF-28 and SRIF-14 by specific methods. Basal glucose levels in the diabetic men were significantly higher than in control subjects (10.2 +/- 1 vs. 5.8 +/- 0.2 mM), but insulin levels were similar (79 +/- 14.2 vs. 93.3 +/- 14.2 pM). The diabetic men had significantly lower basal SRIF-28 levels than the control subjects (11.4 +/- 0.6 vs. 14.6 +/- 1.0 pM, P = 0.017). After fat intake, SRIF-28 levels throughout the 4 h of study were indistinguishable in the two groups (270 vs. 292% of basal). Basal SRIF-14 and SLI levels were not significantly different in the two groups, and SRIF-14 and SLI concentrations rose similarly after the meal. There were no correlations between basal SRIF-28 and glucose or insulin levels.(ABSTRACT TRUNCATED AT 250 WORDS)

Effects of acute and chronic cocaine administration on somatostatin level and binding in the rat brain

The effects of acute and chronic cocaine (40 mg/Kg i.p.) in vivo administration, on 125I-Tyr 11-somatostatin binding and somatostatin-like immunoreactivity (SLI) in the rat frontoparietal cortex, hippocampus and olfactory bulb were explored. Acute and chronic cocaine administration did not affect the levels of SLI in the three brain areas studies. Acute cocaine administration resulted in an 55% and 32% decrease in the total number of specific somatostatin receptors in the hippocampus and olfactory bulb respectively, but not in the frontoparietal cortex. Somatostatin receptor affinity increased in the hippocampus and was unaltered in frontoparietal cortex and olfactory bulb. After two weeks of daily cocaine injections the somatostatin binding in the hippocamus and olfactory bulb returned to control values. The in vitro addition of cocaine to a brain membrane preparation obtained from untreated rats did not markedly affect somatostatin binding characteristics. These results are suggestive of a possible role for somatostatin in the limbic structures as a response to cocaine administration.

Effect of haloperidol withdrawal on somatostatin level and binding in rat brain

The effects of withdrawal on the level and specific binding of somatostatin in the frontoparietal cortex and hippocampus of the rat after chronic haloperidol treatment were examined using 125I-Tyr11 somatostatin as tracer. One week after haloperiodol withdrawal the number of specific somatostatin receptors in both brain areas returned to control values, after having decreased as the result of chronic administration. Neither administration of haloperidol nor withdrawal of it affected the levels of somatostatin-like immunoreactivity (SLI) in the two brain areas studied. The return of the somatostatin receptor number to control values after haloperidol withdrawal may be related to the motor side-effects that are clinically observed when the haloperidol treatment is terminated.

A Characterization of Immunoreactive Somatostatin in Human Milk

In the present work, somatostatin-like immunoreactivity (SLI) in human milk was characterized. In the early postpartum period, SLI levels were highest on the first day after delivery, and then gradually declined. From the fifth day postpartum, SLI levels in milk seemed unchanged. On the fifth day after delivery, milk SLI was significantly (p less than 0.01) higher than plasma SLI (126.3 +/- 11.7 vs. 17.6 +/- 1.1 pmol/L). The results indicate an active transport from blood or synthesis of somatostatin within the mammary gland. Gel filtration studies of skimmed milk, as well as milk exposed to urea and HCl, and aspirated milk from the human premature newborn, revealed that the main portion of milk SLI either represents somatostatin covalently bound to a larger protein, or more likely, a high molecular weight variant of somatostatin.

A Characterization of Immunoreactive Somatostatin in Human Milk

In the present work, somatostatin‐like immunoreactivity (SLI) in human milk was characterized. In the early postpartum period, SLI levels were highest on the first day after delivery, and then gradually declined. From the fifth day postpartum, SLI levels in milk seemed unchanged. On the fifth day after delivery, milk SLI was significantly (p < 0.01) higher than plasma SLI (126.3 ± 11.7 vs. 17.6 ± 1.1 pmol/L). The results indicate an active transport from blood or synthesis of somatostatin within the mammary gland. Gel filtration studies of skimmed milk, as well as milk exposed to urea and HCl, and aspirated milk from the human premature newborn, revealed that the main portion of milk SLI either represents somatostatin covalently bound to a larger protein, or more likely, a high molecular weight variant of somatostatin.

Cerebrospinal fluid levels of immunoreactive substance P and somatostatin in patients with multiple sclerosis and inflammatory CNS disease

Cerebrospinal fluid (CSF) levels of substance-P like immunoreactivity (SPLI) and somatostatin-like immunoreactivity (SLI) were measured in 43 patients with multiple sclerosis (MS), differentiated according to course and activity of the disease, in 23 patients with inflammatory disease of known bacterial or viral etiology and in 16 control patients using specific radioimmunoassay. SPLI and SLI levels were not significantly different from controls in MS patients whereas SLI was significantly increased in patients with infectious disease of central nervous system and/or subarachnoidal space. It is assumed that CSF SPLI and SLI cannot serve as a diagnostic or prognostic indicator of disease state in multiple sclerosis. Analysis of immunoreactivity by reverse phase HPLC-RIA revealed marked molecular heterogeneity of both neuropeptides.

Somatostatin‐Like Immunoreactivity in the Cerebrospinal Fluid of Aged Patients with Parkinson's Disease

Cerebrospinal fluid (CSF) somatostatin concentrations were measured in 35 aged patients with Parkinson's disease (mean age, 79.5 years) and 11 control subjects (mean age, 82.3 years). In patients with Parkinson's disease the levels of somatostatin-like immunoreactivity were lower than in controls (P less than .02); these values were lowest in the untreated group. Somatostatin-like immunoreactivity levels in the CSF tended to increase with treatment but not significantly (P = .11). Somatostatin values were not correlated to age, sex, or duration of the disease. Somatostatin concentrations tended to be lower in more severely affected patients with higher scores on the Hoehn and Yahr (P = .13) and Webster staging scales (P = .13) and lower scores on Mini-Mental State (P = .10), but without statistical significance for these correlations.

Plasma Somatostatin-Like Immunoreactivity during Growth-Hormone-Releasing Hormone Therapy in Non-Growth-Hormone-Deficient Children

To date, the effects of long-term growth hormone (GH)-releasing hormone [GHRH(1-29)-NH2] treatment on the plasma concentrations of somatostatin-like immunoreactivity (SLI) remain undefined. In the present study, the effect of GHRH(1-29)-NH2 therapy on plasma SLI levels has been studied in 11 non-GH-deficient children. The pattern of administration was 5 micrograms/kg body weight, given subcutaneously once every day. There was no significant change in plasma SLI levels after bolus injection of GHRH(1-29)-NH2 before and during GHRH(1-29)-NH2 therapy. However, plasma SLI rose in basal plasma and nocturnal sleep after 3 months of GHRH(1-29)-NH2 therapy and remained the same during 6 months of treatment with GHRH(1-29)-NH2. The reason for this finding is uncertain, but an increase in SLI release from the enteroinsular axis is a possible explanation. The association of our findings with the role of the circulating SLI on nutrient homeostasis and the effects of GNRH on growth velocity is discussed.

Somatostatin Infused during Acute Pancreatitis Retains Its Biological Activity

Somatostatin (SST) is used in the treatment of acute pancreatitis (AP) to inhibit pancreatic exocrine secretion, which represents one of the goals of medical treatment in this disease. Its therapeutic efficacy, however, is poor. One hypothesis, which has not yet been investigated, is that i.v. SST might be broken down by blood proteolytic enzymes. In order to evaluate the structural integrity and biological activity of infused SST, somatostatin-like immunoreactivity (SLI) and levels of pancreatic enzymes were monitored in the blood stream during the infusion of SST-14 (3,5 micrograms/kg/h for 48 h) in eight patients with severe acute pancreatitis. SLI was measured by both radioimmunoassay (RIA) and high-pressure liquid chromatography (HPLC). The results indicate that SLI levels increase promptly after the beginning of infusion, with a slower increase between 6 and 36 h, and a rapid increase again at 48 h. HPLC analysis shows a single peak of SLI with the same retention time as standard SST-14. Total amylase, lipase, and trypsinogen significantly decreased compared with pretreatment values (48, 63.1, and 77.4%, respectively) after 24 h of SST infusion, while a decrease in elastase 1 (62.6%) was observed later at 48 h. These results indicate that in severe AP, somatostatin recovered in plasma retains its biological activity: it inhibits pancreatic circulating enzymes, an action not influenced by breakdown of the peptide, as demonstrated by HPLC of the SLI measured in plasma.

Impaired somatostatin response to orally administered glucose in Type II diabetes entails both somatostatin-28 and -14 and is associated with deranged metabolic control

We have investigated the effects of hyperglycemia in Type II diabetic patients on the somatostatin response to oral glucose. In these patients hyperglycemia prevailed (11.8 +/- 1.4 mmol/l) and was markedly increased to a maximum of 18.9 +/- 1.0 mmol/l following the ingestion of 75 g of glucose. The rise in blood glucose following glucose ingestion failed to induce a rise in plasma levels of somatostatin-like immunoreactivity. Biostator-regulated insulin infusion normalized fasting levels of blood glucose and reduced the hyperglycemia following glucose ingestion, i.e. blood glucose now rose from 4.6 +/- 0.1 to a maximum of 7.3 +/- 0.8 mmol/l. This moderate rise in blood glucose was accompanied by a significant (p less than 0.05) rise in somatostatin-like immunoreactivity. Somatostatin-28 and somatostatin-14 were separated using a Sephadex G-50 fine column. Biostator treatment suppressed plasma levels of both peptides during fasting conditions. Treatment was also accompanied by a rise in both peptides during the first hour following glucose ingestion; this rise did not occur in the untreated state. lack of somatostatin response to glucose in non-insulin-dependent diabetes mellitus is associated with deranged metabolic control. Unresponsiveness to glucose entails the secretion of both somatostatin-28 and -14.

Effects of insulin-induced hypoglycemia on somatostatin level and binding in rat cerebral cortex and hippocampus

The effects of severe insulin-induced hypoglycemia on somatostatin level and specific binding in the cerebral cortex and hippocampus were examined using 125I-Tyr 11-somatostatin as a ligand. Severe insulin-induced hypoglycemia did not affect the level of somatostatin-like immunoreactivity in the brain areas studies. However, the number (but not the affinity) of specific somatostatin receptors was significantly decreased in membrane preparation from the hippocampus but not in the cerebral cortex at the onset of hypoglycemic coma (5–10 min). Administration of glucose at the onset of hypoglycemic coma brought about extensive recovery of hippocampal somatostatin receptor number. These results suggest that glucose modulates the somatostatin receptor in the rat hippocampus. The physiological significance of these findings remains to be clarified.

Effect of cysteamine on levels of somatostatin-like immunoreactivity and catecholamines and on electroencephalogram in the rat brain

Cysteamine (CYS) is known to be a quite specific depletor of somatostatin in the rat brain. In the present study we investigated the effect of CYS (100 mg/kg, 300 mg/kg, subcutaneously) on levels of somatostatin-like immunoreactivity (SLI) in the brain and cerebrospinal fluid, on catecholamines in the cortex, and on spectral cortical electroencephalogram (EEG) of rat. SLI was decreased in both the cortex and the striatum (p < 0.05) of CYS-treated rats, but no change was seen in SLI of CSF. Cortical levels of dopamine, noradrenaline and homovanillic acid were decreased (p < 0.05) following administration of either dose of CYS. In EEG, during mobility both the frontal and occipital peak (F p) and mean (F m) frequencies were slowed (p < 0.05). Frontally, the amplitude of the frequency bands 1.5–3Hz and 3–5Hz was increased (p < 0.05). During immobility the F p and F m were also slowed. In frequency bands of 3–5Hz, 5–10Hz the amplitude was decreased (p < 0.05), indicating that, in addition to theta frequency, the low voltage fast activity is also affected by CYS. According to our results, both the cortical intrinsic neurons containing somatostatin and also the ascending catecholaminergic systems are affected after the single administration of CYS concomittantly with, but not necessarily related to, changes in different frequency bands in EEG.

Effect of cysteamine on somatostatin-like immunoreactivity in the amygdala-kindled rat brain

Previous studies have shown that a somatostatin-depleting drug, cysteamine (CYS), suppresses kindled seizures. However, no data is available concerning the levels of somatostatin-like immunoreactivity (SLI) in the kindled rat brain after CYS administration. In the present study, we used radioimmunoassay to measure SLI in the frontal cortex, amygdala + piriform cortex, hippocampus, striatum and hypothalamus: 1) in control rats, 2) in amygdala-kindled rats decapitated 14 days after the last stimulus, and 3) in amygdala-kindled rats decapitated 14 days after the last stimulus but treated either 11 days or 4) 4 hours before decapitation with CYS (100 mg/kg, subcutaneously). The results showed that, compared to controls, in kindled rats SLI was elevated both in the ipsi lateral (28%, p = 0.0372) and contralateral (17%, p = 0.0078) frontal cortex. Compared to kindled rats, CYS given 4 hours before decapitation decreased SLI in the frontal cortex (to 71%, p = 0.0066) and hippocampus (to 72%, p = 0.0027), but compared to the controls, only in the hippocampus. In rats given CYS 11 days before decapitation, SLI did not differ from either the controls or from the kindled rats. In conclusion, the somatostatinergic system is affected in amygdala-kindling; but the relationship of anatomical localization and the magnitude of CYS-induced decrease of SLI to elevated seizure threshold needs to be studied further.

Gastrin and Somatostatin Levels in Patients with Gastric Cancer

Gastrin and somatostatin-like immunoreactivity (SLI) levels were studied by means of radioimmunoassay in peripheral venous blood of healthy volunteers and patients suffering from gastric adenocarcinoma or duodenal and gastric ulcers. Gastrin and SLI levels were also evaluated in patients in blood drawn from gastric veins during surgery. The elevations of gastrin and SLI levels were found in patients with gastric cancer as compared with healthy people and patients suffering from ulcers. The impairment of the negative feedback between gastrin and somatostatin secretions in patients with gastric cancer was suggested.

Immunoreactive Substance P and Somatostatin in the Cerebrospinal Fluid of Senile Parkinsonian Patients

The concentration of substance-P-like immunoreactivity (SPLI) and somatostatin-like immunoreactivity (SLI) in the lumbar spinal fluid of senile parkinsonian patients (mean age 77.6 +/- 6.7 years) and senile control patients (mean age 83.5 +/- 5.6 years) were determined by specific radioimmunoassays. Mean SPLI and SLI levels in the control group were 8.1 +/- 2.0 (SD) and 32.5 +/- 12.0 fmol/ml, respectively. The mean SPLI levels were not significantly different in the groups. The mean SLI level was significantly lower in the group of patients with Parkinson's disease (19.8 +/- 9.0 fmol/ml). A comparison with results in patients with senile dementia of Alzheimer type (SDAT) shows that, in addition to clinical and pathological correlations, Parkinson's disease of late onset may share a deficit in somatostatinergic neuromodulation with SDAT.

Cysteamine normalizes cerebral somatostatin level and binding in pentylenetetrazol-kindled rats

Rats were kindled by intraperitoneal injection of pentylenetetrazol (PTZ) (30 mg/Kg) every 48 h. Once kindled, some of the animals received a single injection of cysteamine (200 mg/Kg). Somatostatin-like immunoreactivity (SLI) and 125 I-Tyr 11 -somatostatin binding were measured in the frontoparietal cortex and hippocampus of the two experimental groups and the control rats. After PTZ kindling the following was observed: 1) SLI content was increased in the two areas; 2) Somatostatin receptor affinity decreased in the frontoparietal cortex and was unaltered in the hippocampus; 3) The number of somatostatin receptors decreased in the hippocampus and was unaltered in the frontoparietal cortex. Cysteamine, an agent which depletes brain somatostatin and suppresses kindled seizures in PTZ-treated rats, reversed the altered SLI levels and binding in these rats.

Cortical somatostatinergic system not affected in Alzheimer's and Parkinson's diseases

A reduction in the levels of somatostatin-like immunoreactivity (SLI) and somatostatin binding sites in the cerebral cortex has been previously reported to occur in Alzheimer's disease (AD) and Parkinson's disease with associated dementia. In the present study, the levels of both SLI and high affinity [ 3H]somatostatin binding sites have been measured in the frontal (Brodmann area 9) and temporal (Brodmann area 21) cortices in patients with presenile and senile Alzheimer's disease, and in mentally normal and cognitively impaired cases of Parkinson's disease. The results were compared with those obtained from a group of normal patients matched for age and postmortem delay. No significant changes in SLI or somatostatin binding in the frontal and temporal cortex were found between any of the disease groups. These results suggest that involvement of the somatostatinergic system in AD or Parkinson's disease is not a consistent or primary neurochemical feature of these diseases.